Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NVP-BVB808 |
Synonyms | |
Therapy Description |
NVP-BVB808 is a selective ATP-competitive inhibitor of JAK2 (PMID: 22271575, PMID: 24504330). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NVP-BVB808 | BVB-808 | JAK2 Inhibitor - ATP competitive 15 | NVP-BVB808 is a selective ATP-competitive inhibitor of JAK2 (PMID: 22271575, PMID: 24504330). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK2 R683G JAK2 G935R | cancer | resistant | NVP-BVB808 | Preclinical | Actionable | In a preclinical study, cells expressing the JAK2 R683G/G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575). | 22271575 |
JAK2 V617F JAK2 G935R | hematologic cancer | resistant | NVP-BVB808 | Preclinical | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 G935R double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575). | 22271575 |
FLT3 exon 14 ins | hematologic cancer | sensitive | NVP-BVB808 | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing FLT3-ITD were sensitive to treatment with NVP-BVB808 in culture, demonstrating decreased cell viability (PMID: 29296813). | 29296813 |
JAK2 R683G JAK2 E864K | cancer | resistant | NVP-BVB808 | Preclinical | Actionable | In a preclinical study, cells expressing the JAK2 R683G/E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575). | 22271575 |
JAK2 V617F JAK2 E864K | hematologic cancer | resistant | NVP-BVB808 | Preclinical | Actionable | In a preclinical study, immune cells expressing the JAK2 V617F and JAK2 E864K double mutation demonstrated resistance to NVP-BVB808 in culture (PMID: 22271575). | 22271575 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|